According to sources, the European Union is negotiating advance purchase deals of potential COVID-19 vaccines with Moderna, Sanofi, Johnson & Johnson, BioNtech and CureVac, as reported in Investing.
"We are in talk with several companies on possible COVID-19 vaccines," revealed a European Commission spokesman, declining to comment on specific companies.
The European Union is negotiating a supply of 200 million doses of J&J’s vaccine candidate, the sources said, adding that additional supplies may also be available.
They also plan to secure 300 million doses of Sanofi’s potential vaccine developed with GlaxoSmithKline in the second half of next year, the sources revealed. When asked about the negotiations, Sanofi commented that it was in “advanced talks with the EU for the delivery of 300 million doses".
BioNtech and CureVac, which have already been offered EU funds to develop their vaccines, declined to comment on information that they are in talks with the bloc to purchase their vaccines in advance.
A third source said the bloc was renegotiating the deal struck with AstraZeneca by Germany, France, Italy and the Netherlands to ensure all EU states had equal access to the doses secured in its initial deal. The source said the discussion was backed by the four countries which signed the first deal. Meanwhile, negotiations were also ongoing with Moderna.
To read more NewsPoints articles, click here.